- Biogen Idec gets option to Isis' antisense compound for spinal muscular atrophy
- Biogen Idec and Isis together again, this time for myotonic dystrophy type 1 treatment
- Biogen Idec, Isis pen third antisense drug discovery deal this year
- Biogen Idec, Isis team up yet again in neurology
- Biogen, Ionis sign new $1.1bn pact in SMA
Ask The Analyst
Please Note: Click here for more information on the Ask the Analyst service.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.